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Summary
Background: Without known mechanisms of action, thalidomide is used to treat a variety of non-
malignant ‘idiopathic’ diseases. There is increasing concern thatMycobacterium avium subspecies
paratuberculosis (MAP)may be zoonotic. Recently,methotrexate, azathioprine, 6-mercaptopurine
(6-MP), 5-aminosalicylic acid (5-ASA), cyclosporine A, rapamycin, and tacrolimus have been shown
to inhibit MAP growth in culture, indicating that, unknowingly, MAP infections may have been
treated for decades. We herein test the hypothesis that thalidomide may inhibit MAP growth.
Methods: Using the radiometric 14CO2 (Bactec) system we quantified growth kinetics of thalido-
mide (), (+), and () and two components for thalidomide, phthalimide and 1-hydroxypiperidine-
2,6-dione (HPD). We studied four MAP strains (three human isolates, ‘Ben’, ‘Dominic’, and UCF-4,
and a bovine MAP isolate 19698) and three mycobacterial controls (Mycobacterium avium and
bacillus Calmette—Gue´rin (BCG)). Growth was quantified as growth index (GI) and inhibition as
percent decrease in cumulative GI (%—DcGI).
Results: Phthalimide had no dose-dependent inhibition on any strain. Neither thalidomide nor HPD
inhibited M. avium or BCG. MAP inhibition varied; at 64 mg/ml, amongst human isolates, Dominic
was most susceptible: thalidomide (+) = 58%—DcGI and HPD = 46%  DcGI. UCF-4 was next:
thalidomide () = 37%—DcGI and HPD = 40%—DcGI. Ben was least susceptible: HPD = 24%—DcGI.
Conclusions: We have shown, in culture, the heretofore-undescribed inhibition of MAP growth by
thalidomide and its enantiomers. Phthalimide was found to have no anti-MAPactivity, whereas HPD
was found to inhibit MAP growth. These data are compatible with the hypothesis that thalidomide,
likeother ‘anti-inflammatories’ and ‘immunomodulators’mayact, inpart, asananti-MAPantibiotic.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +1 718 584 9000x. 5052/4223;
fax: +1 718 367 4850.
E-mail address: BGAxis@aol.com (R.J. Greenstein).
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In the early 1960s, contemporaneously with the recognition
of the calamitous teratogenic effects of thalidomide, a
patient with uncontrolled erythema nodosum leprosum
was treated with thalidomide as a sedative. Within 72 hoursPublished by Elsevier Ltd. All rights reserved.
Figure 1 A schematic representation of the structure of tha-
lidomide (2-(2,6-dioxo-3-piperidyl)isoindole-1,3-dione) and its
two components, phthalimide (isoindole-1,3-dione) and the
2,6-dioxo-3-piperidyl moiety. Additionally shown is HPD (1-
hydroxypiperidine-2,6-dione), our commercially available surro-
gate for the 2,6-dioxo-3-piperidyl moiety.
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action of thalidomide in leprosy2 and other infectious dis-
eases3 is uncertain. Because of a decrease in inflammation
and pro-inflammatory cytokines, thalidomide is presumed to
act as a non-specific ‘anti-inflammatory’ and ‘immunomo-
dulatory’ agent.4
Thalidomide, 2-(2,6-dioxo-3-piperidyl)isoindole-1,3-
dione, is a conjugate of isoindole-1,3-dione (phthalimide)
and a 2,6-dioxo-3-piperidyl moiety (Figure 1). It is available
as a racemic () mixture as well as the (+) and () enantio-
mers. At present, under strenuous prescription restrictions,
the use of thalidomide has had a remarkable renaissance.5
Thalidomide is used to treat malignancies,6—8 ‘inflamma-
tory’,9,10 ‘autoimmune’,11 and mycobacterial diseases,3,12,13
and it is active against viruses.14
Although controversial,15 there are increasingly compelling
data16—21 (Ref. 21 is a review) that Mycobacterium avium
subspecies paratuberculosis (MAP) may be zoonotic.17
Recently the ‘immune modulators’ methotrexate,18
azathioprine,22 its metabolite 6-mercaptopurine (6-MP),18,22
the ‘anti-inflammatory’ agent 5-aminosalicylic acid (5-ASA),23
and the ‘immune suppressants’ cyclosporineA,24 rapamycin,24
and tacrolimus24 have been shown to inhibit MAP growth in
culture.We concluded that all prior studies that had evaluated
the possible zoonosis of MAP needed to be repeated, as invari-
ably the ‘control’ groups were not placebo as patients would,
unknowingly, have been receiving anti-MAP antibiotics.23
In this study, we tested the hypothesis that the action of
thalidomide could, in a variety of ‘inflammatory,’ ‘autoim-
mune’ and infectious diseases, be due in part to thalidomideFigure 2 Study comparing the bioavailability of agents when the
performed on two MAP isolates, one human (Dominic) and a bovine is
NaOH had no inhibitory activity. The data for the positive NaOH con
index. As a consequence of these data, all the remaining thalidomior one or both of its components acting as an anti-MAP anti-
biotic(s.) If correct, these anti-inflammatory effects would
simply represent a normal, secondary, physiological response
as a causative infection was treated. Accordingly, we studied
thalidomide, its (+) and () enantiomers, and its two compo-
nents (phthalimide as well as 1-hydroxypiperidine-2,6-dione
as a surrogate for thalidomide’s 2,6-dioxo-3-piperidylmoiety).y have been solubilized in either NaOH or DMSO. Studies were
olate (ATCC 19698.) The components of thalidomide dissolved in
trol (ciprofloxacin) are not presented. cGI = cumulative growth
de studies were performed using DMSO.
Figure 3 The effect of adding Tween 80, a detergent intended
to prevent mycobacterial clumping, to the culture medium. The
addition of Tween 80 inhibited the growth of MAP growing in 7H12
broth, with and without 3.2% DMSO. Additionally, the dose-
dependent inhibition that is seen when no detergent is used
(lower graph) was no longer evident when Tween 80 was used
(top graph.) As a consequence of these data, Tween 80 was not
employed in further studies.
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teria including M. avium, its subspecies MAP, and bacillus
Calmette—Gue´rin (BCG) as a representative of the M. tuber-
culosis complex.
Methods
This study was approved by the Research and Development
Committee at the VAMC Bronx NY (0720-06-038) and was
conducted under the Institutional Radioactive Materials Per-
mit (#31-00636-07).
Bacterial culture
Prior to inoculation, cultures were processed as described
previously.18,23,25 In this research, four strains of MAP were
studied. Three were isolated from humans with inflammatory
bowel disease, ‘Ben’ (ATCC 43544), ‘Dominic’ (ATCC 43545;
originally isolated by R. Chiodini26), and UCF-4 (gift of S.
Naser, Orlando, FL, USA19). The fourth MAP strain was a
bovine isolate, MAPATCC 19698. As controls, we additionally
studied three non-MAP mycobacterial strains. The M. avium
subspecies avium strains (hereinafter called M. avium) were
ATCC 25291 (veterinary source) andM. avium 101.27 Our final
non-MAP control was from the M. tuberculosis complex, a
Biosafety level II surrogate for M. tuberculosis, BCG M. bovis
Karlson and Lessel (ATCC 19015). All ATCC were from ATCC
Manassas, VA, USA.
Thalidomide and its agents are difficult to dissolve. So we
studied two different solvents, NaOH and dimethylsulfoxide
(DMSO; Sigma) (Figure 2). Mycobacteria clump during cul-
ture, possibly interfering with antibiotic inhibition studies.
To prevent this occurring, the instruction manual of the
equipment that we use (Bactec 460, Becton Dickinson,
Franklin Lakes, NJ, USA) recommends the use of the deter-
gent Tween 80. However, Tween 80 has been reported to
interfere in mycobacterial antibiotic susceptibility stu-
dies.28 Accordingly, we next evaluated the effect of Tween
80 (Figure 3).
Our positive antibiotic control was clofazimine (used to
treat leprosy29 and in clinical trials of Crohn’s disease15,30).
Our negative control was cycloheximide, a glutarimide anti-
biotic that is from the same family as phthalimide, one of the
two component molecules of intact thalidomide (Figure 1).
The tested agents were thalidomide (), (+), and () and
phthalimide (Sigma).Table 1 Clofazimine %DcGI
Clofazimine mg/ml MAP
Human
Dominic UCF-4 Ben
1 99% ND 99%
4 99% ND 99%
16 99% ND 99%
64 99% ND 99%
%DcGI, percent negative delta of cumulative growth index comp
paratuberculosis; BCG, bacillus Calmette—Gue´rin; ND, no data availabFinally, we wished to study the effect of the other
component of thalidomide, the 2,6-dioxo-3-piperidyl moi-
ety (Figure 1). The molecule with the greatest homology
that we were able to identify commercially was 1-hydro-
xypiperidine-2,6-dione (HPD; Figure 1) at the Rare Chemi-
cal Library at Aldrich (Cat. No. R159646). We purchased all
the remaining 15 mg of HPD available at Aldrich (personal
communication, Cyndi Lembke, Scientist Sigma-Aldrich
Technical Service, e-mail: techserv@sial.com). Custom
synthesis of HPD is possible for those having the resourcesMycobacterium
avium
Mycobacterium bovis
Bovine Bovine BCG
19698 25291 101 19015
98% 98% 95% 95%
98% 98% 96% 96%
98% 98% 96% 96%
99% 98% 96% 96%
ared to solvent control; MAP, Mycobacterium avium subspecies
le.
Table 2 Cycloheximide %DcGI
Cycloheximide mg/ml MAP Mycobacterium
avium
Mycobacterium bovis
Human Bovine Bovine BCG
Dominic UCF-4 Ben 19698 25291 101 19015
1 16% 9% 7% 17% 49% 13% 9%
4 6% 4% 1% 4% 40% 3% 38%
16 12% 9% 3% 3% 14% 18% 27%
64 19% 24% 5% 3% 53% 2% 68%
%DcGI, percent negative delta of cumulative growth index compared to solvent control; MAP, Mycobacterium avium subspecies
paratuberculosis; BCG, bacillus Calmette—Gue´rin.
Table 3 Racemic thalidomide () %DcGI
Thalidomide () mg/ml MAP Mycobacterium
avium
Mycobacterium bovis
Human Bovine Bovine BCG
Dominic UCF-4 Ben 19698 25291 101 19015
1 2% 8% 0% 4% 34% 20% 13%
4 4% 12% 1% 8% 37% 5% 4%
16 9% 14% 8% 7% 28% 6% 32%
64 31% 1% 11% 26% 25% 14% 76%
%DcGI, percent negative delta of cumulative growth index compared to solvent control; MAP, Mycobacterium avium subspecies
paratuberculosis; BCG, bacillus Calmette—Gue´rin.
Table 5 Thalidomide () %DcGI
Thalidomide () mg/ml MAP Mycobacterium
avium
Mycobacterium bovis
Human Bovine Bovine BCG
Dominic UCF-4 Ben 19698 25291 101 19015
1 6% 16% 5% ND ND 17% 32%
4 1% 18% 2% ND ND 3% 32%
16 15% 35% 9% ND ND 6% 55%
64 22% 37% 11% ND ND 27% 70%
%DcGI, percent negative delta of cumulative growth index compared to solvent control; MAP, Mycobacterium avium subspecies
paratuberculosis; BCG, bacillus Calmette—Gue´rin; ND, no data available.
Table 4 Thalidomide (+) %DcGI
Thalidomide (+) mg/ml MAP Mycobacterium
avium
Mycobacterium bovis
Human Bovine Bovine BCG
Dominic UCF-4 Ben 19698 25291 101 19015
1 4% 2% 4% ND ND 4% 63%
4 1% 8% 9% ND ND 5% 34%
16 14% 16% 3% ND ND 16% 71%
64 58% 24% 1% ND ND 19% 51%
%DcGI, percent negative delta of cumulative growth index compared to solvent control; MAP, Mycobacterium avium subspecies
paratuberculosis; BCG, bacillus Calmette—Gue´rin; ND, no data available.
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Table 7 1-Hydroxypiperidine-2,6-dione (HPD) %DcGI
HPD mg/ml MAP Mycobacterium
avium
Mycobacterium bovis
Human Bovine Bovine BCG
Dominic UCF-4 Ben 19698 25291 101 19015
1 5% 28% 6% 7% 4% 12% ND
4 7% 16% 3% 9% 47% 52% ND
16 18% 33% 0% 15% 22% 21% ND
64 46% 40% 24% 28% 21% 36% ND
%DcGI, percent negative delta of cumulative growth index compared to solvent control; MAP, Mycobacterium avium subspecies
paratuberculosis; BCG, bacillus Calmette—Gue´rin; ND, no data available.
Table 6 Phthalimide %DcGI
Phthalimide mg/ml MAP Mycobacterium
avium
Mycobacterium bovis
Human Bovine Bovine BCG
Dominic UCF-4 Ben 19698 25291 101 19015
1 23% 14% 16% 16% 49% 27% 38%
4 19% 9% 4% 22% 49% 45% 27%
16 3% 5% 8% 8% 48% 30% 32%
64 9% 1% 8% 7% 14% 52% 37%
%DcGI, percent negative delta of cumulative growth index compared to solvent control; MAP, Mycobacterium avium subspecies
paratuberculosis; BCG, bacillus Calmette—Gue´rin.
e258 R.J. Greenstein et al.who wish to replicate our experiments (Michelle M. Strake,
SAFC Supply Solutions, St. Louis, MO, USA, e-mail: Michel-
le.Strake@sial.com).
Aliquots of chemicals being evaluated were prediluted,
stored at 80 8C in 50% DMSO (Sigma) and 50% water or 0.5 M
NaOH, thawed, used once and discarded. Volumes of diluents
were adjusted so that the final concentration in each Bactec
vial was always 3.2% DMSO or 3.2 mM NaOH. Chemicals were
tested in serial dilutions from 1 mg/ml to 64 mg/ml.
Our method of reporting mycobacterial growth inhibition
has been previously described.23 In brief, the cumulative
growth index (cGI) is calculated until the day prior to any
of the Bactec vials reaching the manufacturer-determined
‘999’ assay limit. Vials with compounds being evaluated are
compared to the control, which always contains an equal
volume of the diluent that was used (in the majority of these
experiments, 3.2% DMSO). Inhibition is expressed as %DcGI,
and enhancement as %+DcGI.23 Data for the effect of test
agents on mycobacterial growth are presented as a compar-
ison of the effect of each agent tested on each of the
mycobacterial strains in tabular form (Tables 1—7).
Table 1 is the positive control, clofazimine. Table 2 is the
negative control, cycloheximide. Table 3 is the racemic ()
mixture of thalidomide. Table 4 is the positive isomer, thali-
domide (+). Table 5 is the negative isomer, thalidomide ().
Table 6 is one moiety of intact thalidomide, phthalimide (iso-
indole-1,3-dione) andTable 7 isHPD (1-hydroxypiperidine-2,6-
dione), the surrogate for the 2,6-dioxo-3-piperidylmoiety, the
other thalidomide moiety (see Figure 1). When duplicates are
presented, error bars are  standard deviation (SD).Results
Data are presented in two ways — either for individual
bacterial strains (Figures 2—8) or as data for individual
chemical agents tested (Tables 1—7).
Our positive experimental control was clofazimine. There
was96%DcGI at 1 mg/ml, the lowest dose evaluated for all
mycobacterial strains studied (Table 1). The negative control
was cycloheximide, a glutarimide antibiotic that is from the
same family as phthalimide, one of the two moieties that
constitute thalidomide (see Figure 1). Cycloheximide had no
dose-dependent inhibition on any MAP or M. avium strain
tested (Table 2).
Dose-dependent inhibition of MAP Dominic and MAPATCC
19698 was observed with thalidomide () and HPD when the
solvent was DMSO (Figure 2, right hand graphs). In contrast,
no such inhibition was observed when the solvent was NaOH
(Figure 2, left hand graphs). Accordingly, for the remainder
of the experiments in this study we used DMSO as our
solvent.
We next evaluated the effect of adding or withholding the
detergent Tween 80 in our assay. Tween 80 inhibited the
growth of MAP Dominic by 15% in the control 7H12 medium in
the Bactec control vials (data not presented) and by 37%
when DMSO was added to the culture vial (Figure 3, control
values top and bottom graphs). Dose-dependent inhibition
was seen when the (+) and () thalidomide enantiomers were
incubated without Tween 80 (Figure 3, bottom graph). In
contrast, when Tween 80 was added (Figure 3, top graph) no
inhibition was observed with thalidomide (+) and ().
Figure 4 Comparison of three different inocula, 2.9  104,
1.5  104, and 0.7  104 CFU per Bactec vial. Dose-dependent
inhibition was more pronounced when the higher counts were
used. As a consequence of these data, we continued to passage
when the cumulative growth index (cGI) was as close to 500 as
was practicable.
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our experiments.
For experimental reproducibility, we passaged our MAP
during log phase growth as close to a GI of 500 as was
practicable. Our dilution protocol resulted in a relatively
consistent MAP inoculation of approx. 3  104 CFU per vial.
We next evaluated the effect of doubling dilutions (result-
ing in approx. 1.5  104 and approx. 0.7  104 CFU/vial) of
MAP Dominic (Figure 4). Previously, our data indicated that
our published protocol of inoculating approx. 3  104 CFU at
a MAP GI of 500 provides satisfactory inhibition curves
within an acceptable incubation time. In these studies,
the lowest inoculation values (Figure 4, bottom graph)
did not satisfactorily demonstrate the dose-dependant inhi-
bition that is evident at the higher CFU inoculations
(Figure 4, upper two graphs). Accordingly we continued
to passage at a GI of approx. 500 for the remainder of these
experiments.
We found that inhibition patterns varied from MAP strain
to strain and the various thalidomide enantiomers and moi-
eties. For example, thalidomide () inhibited Dominic
(31%DcGI by 64 mg/ml; Table 3) but thalidomide (+) caused
more inhibition (58%DcGI by 64 mg/ml; Table 4 and
Figure 5). In contrast human MAP UCF-4 showed greater
dose-dependent inhibition with thalidomide () (37%DcGI
DcGI by 64 mg/ml; Table 5 and Figure 6).
Phthalimide (Table 6), one of the two moieties that
combine to form the thalidomide molecule, exhibited even
less inhibition than our experimental negative control cyclo-
heximide (Table 2). In marked contrast HPD, the other moiety
of thalidomide, resulted in dose-dependent inhibition of MAP
(Table 7 and Figures 2 and 6). HPD did not cause dose-
dependent inhibition on M. avium (Figure 7 and Table 7) or
BCG (Table 7).
As culture controls, we studied three other mycobacterial
strains. Two were M. avium subspecies avium, ATCC 25291
and 101. Other than the positive control, clofazimine
(Table 1), none of the other agents tested showed any
dose-dependent inhibition against these twoM. avium strains
(Tables 2—7 and Figure 7). Finally, we studied a Biosafety
level II surrogate from the M. tuberculosis complex, BCG M.
bovis Karlson and Lessel (ATCC 19015.) Other than the posi-
tive control (Table 1), none of the other agents tested
exhibited any inhibition on BCG (Figure 8 and Tables 2—6).
There was no HPD left to test against BCG.
Discussion
The empirical therapeutic efficacy of thalidomide in ‘inflam-
matory’,9,10 ‘autoimmune’,11,31,32 and mycobacterial dis-
eases1,3,12—14 is accepted, although the mechanism of
action not understood. The hypothesis that thalidomide
might act as an antibiotic has previously been tested,2,33,34
but has never been confirmed. Our data are compatible with
the hypothesis that racemic thalidomide and its enantiomers
inhibit the growth of some strains of MAP in culture. We
additionally infer, from our HPD data, that it is the 2,6-dioxo-
3-piperidyl moiety and not the phthalimide component of
thalidomide that has anti-MAP activity. The lack of inhibition
with Ben, a humanMAP isolate, explains why some individuals
with putative MAP infections may not respond to treatment
with thalidomide.Our findings are subtle and the experimental controls are
critical in analyzing the data. We used DMSO as our diluent
(Figure 2). It is of concern that in a choriocapillary endothe-
lial cell proliferation assay, DMSO alone was found to be as
inhibitory as thalidomide.35 To control for possible non-spe-
cific DMSO inhibition, in our assay we added 3.2% DMSO to
every Bactec vial, whether it be a control vial or not, and
irrespective of the varying amount of agent that was added to
any individual vial. Additionally, the other negative controls
(cycloheximide and phthalimide) and mycobacterial strains
(M. avium and BCG) did not exhibit inhibition when exposed
Figure 6 Studies performed on two additional strains of MAP
that had been isolated from humans, Ben and UCF-4. Note that
for both strains the HPD moiety of thalidomide was the most
effective agent, whereas phthalimide (open circles), the other
moiety of thalidomide, showed no inhibition.
Figure 5 Studies performed using Dominic on the enantiomers
of thalidomide. Note that the enantiomer thalidomide (+) was
the most effective agent for this strain (see also Tables 4—6).
Error bars are SD.
Figure 7 Studies with the control M. avium subspecies avium
strains ATCC 2591 and 101. Note that there was no dose-depen-
dent inhibition of any agent tested on either strain.
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cannot be ascribed to non-specific DMSO anti-MAP and anti-
mycobacterial activity.
The positive control, clofazimine, has unquestioned effi-
cacy in another mycobacterial disease, leprosy. Our data
show that clofazimine inhibits MAP growth in culture. The
negative control was cycloheximide, a glutarimide antibio-
tic. Phthalimide, one of the two constituent components of
thalidomide, is also a glutarimide antibiotic. Our data showFigure 8 Results of the study performed on a Biosafety level II
surrogate for the M. tuberculosis complex, BCG M. bovis Karlson
and Lessel (ATCC 19015). Note that the inhibition is shown only
with our usual negative control, phthalimide, and that it was not
dose-dependent. In contrast, racemic thalidomide (solid circles)
and thalidomide () actually may have caused a dose-dependent
enhancement of growth.
Table 8 Comparison of ‘high’ dose of thalidomide in malignancies with ‘low’ dose used in infectious, ‘autoimmune’, and
‘inflammatory’ diseases
Thalidomide dosage
‘High’ dose (eukaryotic malignancies) ‘Low’ dose (infectious/‘autoimmune’/‘inflammatory’ diseases)
Disease Dosage
(mg/day)
Duration Citation Disease Dosage
(mg/day)
Duration Citation
Metastatic renal cell Ca 200 Chronic 42 ENL 50—200 Chronic 44
1200 Chronic 42
1200 Acute 43
Multiple myeloma 1200 Acute 7,45 Crohn’s disease 50—200 Chronic 9
Indolent lymphoma 800 Chronic 46 Rheumatoid arthritis 600 Acute 47
50—100 Chronic
Prostate cancer 100 Chronic 48 Apthous ulcers (HIV/AIDS) 200 Chronic 49
1200 Acute
Malignant melanoma <400 Chronic 50 SLE 25—100 Chronic 11
Sarcoidosis 50 Chronic 51
ENL = Erythema nodosum leprae; SLE = Systemic lupus erythematosus.
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inhibition on MAP in culture. We conclude that the inhibition
we found with racemic thalidomide, the two enantiomers of
thalidomide, and HPD (our surrogate for the 2,6-dioxo-3-
piperidyl moiety) cannot be ascribed to non-specific inhibi-
tion of MAP in culture.
In addition to our chemical controls, we employed three
mycobacterial controls from two other mycobacterial spe-
cies: M. avium subspecies avium and BCG, from the M.
tuberculosis complex. Our data show that none of the che-
mical agents tested from the thalidomide family induced a
dose-dependent inhibition in our control strains. We con-
clude that our MAP inhibition is mycobacterial (sub)species
specific.
Since Mycobacterium leprae has never been successfully
cultured in the laboratory,36 M. leprae cannot be cultured in
our exquisitely sensitive radiometric 14CO2 Bactec system.
This lack of a sufficiently sensitive assay might explain prior
failures to identify thalidomide as an antibiotic. We con-
clude, that in part, the effect of thalidomide in erythema
nodosum leprosum might be ascribed to anti-M. leprae
activity of thalidomide and its 2,6-dioxo-3-piperidyl moiety.
Both M. leprae and MAP are amongst the most slowly
replicating mycobacteria. Other anti-M. leprae and anti-
MAP antibiotics require months to achieve a clinical
response. Thus, the rapidity of the clinical response observed
when thalidomide is effective in the therapy of erythema
nodosum leprosum1 cannot be solely ascribed to a possible
anti-M. leprae antibiotic action. Phthalimide is a glutarimide
antibiotic that has a multiplicity of actions on eukaryotic
cells, including inhibiting DNA37 and protein38,39 synthesis.
We therefore hypothesize that there may be a synergistic
interplay between thalidomide metabolites,40,41 the 2,6-
dioxo-3-piperidyl moiety and/or phthalimide. This hypoth-
esis can only be tested in an animal model, where the
individual thalidomide components can be administered
alone or in combination. Since, in this study, we have appar-
ently used the last commercially available 15 mg of HPD,testing our hypothesis in an animal model will be both
challenging and expensive.
Finally, thalidomide (Table 8),7,9,11,42—51 like methotrex-
ate and 6-MP,18 is used in ‘high’ and ‘low’ doses. The ‘high’
doses are used to treat eukaryotic malignancies and the ‘low’
dose to treat infectious, ‘autoimmune’, and ‘inflammatory’
diseases. These data are compatible with the thesis that
thalidomide may have prokaryotic antibiotic in addition to
eukaryotic anti-neoplastic activity.
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